

PATIENT-SPECIFIC DOSIMETRY

ACKNOWLEDGMENT

This invention was supported in part by NIH Grants CA56794 and CA42768. The U.S. Government may have rights in this invention.

CROSS-REFERENCE TO RELATED APPLICATION

This application is related to U.S. Serial No. 60/088,327, filed June 4, 1998.

INTRODUCTIONTechnical Field

The invention relates to methods of optimizing the therapeutic dose of a radiopharmaceutical to be given to a patient for treatment of a disease.

Background

Radiopharmaceuticals are becoming more widely used for the treatment of disease in patients. Research continues, however, to elucidate the specifics of how to most effectively utilize radiopharmaceuticals in therapy. For example, the optimally effective administered activity of the radiopharmaceutical for any given radiopharmaceutical is not immediately evident. There is a substantial variance among patients in how long radiopharmaceuticals are retained in the body, so that a patient who retains a given radiopharmaceutical for a long time will get a much higher radiation dose than a similar-sized patient who retains the given radiopharmaceutical for a shorter period of time. This is not predictable from patient weight or body surface area alone. With varying clearance rates of any given radiopharmaceutical, differing radiation doses would be delivered to each patient per millicurie of the radiopharmaceutical administered, even if the patients have identical masses or body surface areas.

When conventional methods of dosing are used, e.g., simply based on the patient's size, there is the potential for causing adverse effects, on the one hand, and failing to provide an

1 effective dose, on the other hand. Overdosing with the radiopharmaceutical may have dire
2 consequences including damage to normal tissues, myeloablation, and death. Myeloablation
3 typically necessitates hematopoietic stem cell reintroduction (usually a bone marrow transplant)
4 in order for the patient to recover hematopoietic function. This is often an undesirable further
5 procedure, especially in the treatment of seriously ill patients. Underdosing of the
6 radiopharmaceutical is also not desired. If a standard dose below the known toxicity level for the
7 particular radiopharmaceutical is given to each patient, then some patients may get enough
8 radioactivity for treatment of the disease, but many others will not get enough. Repeat dosing is
9 not a practicable alternative because of cost, resource, and patient general health considerations.
10 Furthermore, it is extremely difficult to predict whether a certain patient in whom little or no
11 effect has been seen with the standard therapy dose should be given a repeat dose, since the poor
12 results may be due to some other physiological factors. If a repeat therapy dose is desired, it is
13 difficult to ascertain how long after the initial dose the repeat dose should be administered and
14 whether the repeat dose should be at full strength or a fraction of the initial dose.

15 Thus, it is highly desirable to adjust for these variabilities on an individual patient basis.
16 Patient-specific dosimetry that takes into account the individual patient's pharmacokinetics and
17 the radiation energy absorbed within the whole body of the patient is needed to determine the
18 most appropriate dose for the individual patient.

19 20 SUMMARY OF THE INVENTION

21 The invention is a simplified dosimetric approach of general clinical and research
22 applicability for treatment of patients with radiopharmaceuticals, and is based on patient-specific
23 characteristics.

24 The invention is a method of establishing an optimally effective dose for administration
25 of a radiopharmaceutical to a patient for treatment of disease. The method is based on various
26 aspects of the radiopharmaceutical and how it acts within the body of the patient. Thus, patient-
27 specific characteristics, such as patient body mass and pharmacokinetics, and more general
28 characteristics based on the radionuclide of the radiopharmaceutical are taken into account.

29 Other aspects of the invention include a computer software program or a computer
30 system for implementing the method.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates the relationship of the fat component of the individual with respect to the lean component of the same individual, thus defining the "lean person (inner ellipsoid) within the fat person (outer ellipsoid)" theory of the present invention.

Figures 2 to 5 are flowcharts for the implementation of the methods of the invention in a computer system.

Figure 6 is a schematic representation of a computer system for implementing the invention.

Figure 7 is an example of a semi log paper graph for determination of total body residence time of an ^{131}I -labeled radiopharmaceutical in a particular patient. A best fit line is drawn from the pre-plotted 100% injected activity at time 0 (point in upper left hand corner) through the plotted data points. The x-coordinate of the point where the best fit line intersects the horizontal 37% line is the total body residence time. Data and the best fit line are plotted for the sample calculation. For this example, the residence time is 103 hours.

DETAILED DESCRIPTION OF THE INVENTION

Abbreviations

AH means activity hours.

cGy means centigray. One cGy is equivalent to one rad.

mCi means millicurie.

MEM means maximum effective mass.

MTD means maximum tolerated dose.

TBD means total body dose.

Patient-specific dosimetry is used for calculating the optimally effective dose of a radiopharmaceutical to be administered to a patient in the methods of the invention. This is a significant improvement over previous dosimetry methods, since it allows the radiation dose to be tailored to the specific physiological characteristics, including pharmacokinetics, of the

1 individual patient. Patient-specific dosimetry provides the advantages of maximized efficacy
2 and minimized toxicity. Performance of the data acquisition and calculation steps for the
3 patient-specific dosimetry methods is not burdensome, but may be further assisted by a
4 computer.

5 The patient-specific dosimetry taught herein is a simplified method for determining the
6 therapeutic dose of a radiopharmaceutical to be administered to an individual patient and
7 involves the following two steps: (a) administration of a dosimetric dose of the
8 radiopharmaceutical or its analog followed by sequential measurement of the elimination
9 kinetics of the dosimetric dose, preferably with an appropriately collimated and calibrated
10 gamma camera, or other suitable apparatus, operated in whole body scanning mode (serial
11 anterior and posterior whole body scans), and (b) calculation of the therapeutic dose to be
12 administered to the individual patient. The therapeutic dose of the radiopharmaceutical can then
13 be administered to the patient according to the prescribed protocol for treatment of the disease.

14 In order to establish a patient-specific optimal effective radiation dose, initially, one
15 needs to gather certain data on the individual patient and the radiopharmaceutical, and then this
16 information is combined with information regarding the desired absorbed total body dose for
17 treatment of the specific disease. More specifically, the activity hours, or cumulated activity,
18 measured in units of millicurie hours, for the radiopharmaceutical is determined based on a
19 combination of patient-specific factors (such as the patient's mass or maximum effective mass
20 and the desired total body dose) and general characteristics of the radionuclide. A dosimetric
21 evaluation is then performed on the patient, usually with the use of a lower millicurie amount of
22 the radiopharmaceutical, to get an understanding of the rate at which the radiopharmaceutical is
23 cleared from the patient's body. The dosimetric evaluation provides an indication of the
24 residence time of the radiopharmaceutical for the individual patient. The activity hours are then
25 combined with the residence time and optionally adjusted via an attenuation factor in order to
26 establish the optimum therapeutic dose in millicurie units for treatment of the individual patient.

27 28 **Radiopharmaceutical**

29 The radiopharmaceutical is usually a radioimmunoconjugate, typically an antibody or
30 antibody fragment conjugated to a radiolabel for delivery to a specific target within the body of
31 the patient. The term "radiopharmaceutical" more broadly encompasses any radioactively-

1 labeled targeting moiety, directed to a target within the body. Thus, although *immunoconjugates*
2 are of great value in therapy, the conjugate with which the patient will be treated may have
3 something other than an immunologically active molecule as the targeting moiety. For example,
4 as used herein, the radiopharmaceutical may be a ligand for a receptor. "Radiopharmaceutical"
5 may be even more broadly defined as any pharmaceutical associated with or comprising a
6 radionuclide. The pharmaceutical may be associated with a radionuclide through a chelator,
7 direct chemical bonding, or some other means. The radiopharmaceutical may also consist
8 essentially of a radionuclide. For example, ^{89}Sr is used as a radiopharmaceutical for the
9 treatment of bone pain and Na^{131}I is used as a radiopharmaceutical for the treatment of thyroid
10 cancer. Although neither of these radiopharmaceuticals is specifically attached to a targeting
11 moiety, each is highly useful because it tends to accumulate in the organ in which treatment is
12 desired.

13 While radiopharmaceuticals that move to certain specific sites within the body unassisted
14 or that are made to be directed to the specific sites are most widely used for therapy,
15 administered radiopharmaceuticals which act systemically or in a non-targeting fashion, e.g. to
16 treat metastatic foci throughout the body, may also be used in patient treatment. Calculation of
17 the optimally effective dose for treatment with all radiopharmaceuticals according to the methods
18 of the present invention is advantageous so that treatment efficacy is maximized and toxicity is
19 minimized. Thus, the methods of patient-specific dosimetry taught herein may be used for
20 radiopharmaceuticals generally.

21 In the practice of the methods of the invention, the radiopharmaceutical to be eventually
22 administered to the patient for treatment or an analog of the radiopharmaceutical may be used at
23 the dosimetric evaluation stage. Generally, a single radiopharmaceutical, usually radiolabeled in
24 differing amounts (typically a high millicurie amount for delivery of a therapeutically effective
25 amount of radioactivity and a relatively small millicurie amount for the earlier dosimetric
26 evaluation) is used for patient-specific dosimetry and for treatment. If a radiopharmaceutical
27 analog is to be used, it should be predictive of the residence time of the radiopharmaceutical in
28 the body of the patient. By way of example, the radiopharmaceutical analog may differ from the
29 radiopharmaceutical of interest by virtue of having a different radiolabel (e.g., the
30 radiopharmaceutical may be a particular antibody labeled with ^{90}Y whereas the
31 radiopharmaceutical analog may be the same antibody labeled with ^{111}In), or it may be of a

1 different size (such as an antibody fragment), or the radiolabel may be conjugated to the
2 targeting moiety in a different manner in the analog. Further, the analog may be a type of
3 molecule or particle distinct from the radiopharmaceutical, such as an artificial particle or
4 optically traceable (and non-radioactive) agent for measurement of the patient's clearance rate.
5 The analog should be suitable, however, for use in the dosimetric evaluation, so it should predict
6 therapeutic behavior of the radiopharmaceutical.

8 **Radionuclides**

9 The methods of the present invention may be used without limitation to the type of
10 radionuclide that is included in the radiopharmaceutical, although those radionuclides having
11 greatest utility in a method of treatment of the patient and in a method of establishing the
12 optimally effective dose for treatment will be those that meet certain criteria. These criteria
13 generally include high therapeutic value, ready availability, a physical half-life within a
14 practicable range for dosimetric evaluation and treatment of the patient, and good imaging
15 qualities, either of the radionuclide itself or of an acceptable analog. Radionuclides that emit β
16 particles, photons (x-rays and γ emissions), α particles, Auger electrons, and/or internal
17 conversion electrons or any other emission may be used. A gamma or positron-emitter is
18 preferably used for the dosimetric evaluation. The methods may be advantageously used to
19 optimize dosing for a broad range of radionuclides including ^{111}In , ^{67}Ga , ^{90}Y , ^{131}I , ^{125}I , ^{123}I , ^{32}P ,
20 ^{47}Sc , ^{67}Cu , ^{109}Pd , ^{111}Ag , ^{153}Sm , ^{166}Ho , ^{177}Lu , ^{186}Re , ^{188}Re , ^{199}Au , ^{211}At , ^{212}Bi , ^{233}Ra , ^{225}Ac , ^{213}Bi ,
21 and $^{99\text{m}}\text{Tc}$.

22 The methods taught herein are particularly appropriate for ^{131}I -labeled
23 radiopharmaceuticals as ^{131}I is a combined beta and gamma emitter. The gamma photon from
24 ^{131}I decay, although of high energy, is easily detectable by gamma scintigraphy or a NaI
25 (thyroid) probe. Both methods are suitable for determining the rate of clearance of the tracer
26 from the body of the patient.

27 The use of other radionuclides may require some adjustment to the simplest form of
28 practicing the invention, however. For example, ^{90}Y emits beta particles and little to no gamma
29 radiation, with the result that a radiopharmaceutical having a ^{90}Y radiolabel may be difficult to
30 image via conventional means, such as the typical gamma camera available in hospital nuclear
31 medicine facilities. Imaging of a ^{90}Y -labeled radiopharmaceutical may occur, however, using

1 the Bremsstrahlung emissions from the ^{90}Y radionuclide. Alternatively, an analog for the
2 radiopharmaceutical may be used at the dosimetric evaluation stage of the methods of the
3 invention. A form of the radiopharmaceutical that is radiolabeled with ^{111}In , a radionuclide
4 which is relatively easy to image via conventional means, may be used as a substitute for the
5 ^{90}Y -labeled radiopharmaceutical, for example, so that the ^{111}In -labeled radiopharmaceutical
6 analog may be used to predict the residence time in the patient of the therapeutically effective
7 ^{90}Y -labeled radiopharmaceutical. Similarly, the positron-emitter ^{124}I might be used to predict
8 residence time for ^{131}I therapies. Further, a radiopharmaceutical having an α -emitter, such as
9 bismuth, may be used, but “imaging” at the dosimetric evaluation stage may then comprise blood
10 or urine sampling and counting of the samples to determine the patient-specific residence time.

11 The methods of the present invention are typically practiced using radiopharmaceuticals,
12 and specifically radionuclides, that are not substantially deposited in the bone or bone marrow
13 since avoidance of myeloablation is generally an important aim in the therapy. As will be
14 evident to practitioners in the field, however, deposition of the radionuclide in the bone may be
15 desired (e.g., ^{89}Sr treatment for bone pain) or an acceptable side effect (e.g., where the treatment
16 is supported by bone marrow transplant) for the treatment of certain diseases or disease states.
17 Therefore, the invention may be utilized to optimize dosing even for radiopharmaceuticals that
18 are deposited in the bone or bone marrow.

19 20 **Maximum Tolerated Dose**

21 The maximum tolerated dose (MTD) is usually defined by reference to the relevant
22 patient subpopulation. Typically, one can determine the MTD by doing a dose escalation study
23 for the specific radiopharmaceutical of interest in the patient subpopulation.

24 For example, the patient population may be all patients having a certain disease, such as
25 non-Hodgkin’s lymphoma, defined broadly or narrowly depending on the characteristics of the
26 disease. The patient subgroup or subpopulation in this example may be patients who are
27 refractory to the usual chemotherapy regimen for non-Hodgkin’s lymphoma or perhaps patients
28 who are above a certain age, have low platelet counts, or are immunocompromised due to certain
29 factors. The more narrowly one defines the patient subpopulation to gather useful data on the
30 MTD, the greater confidence that the specific patient to be treated will be given the appropriate
31 and optimally effective radiation dose.

1 Of course, it is possible to establish an MTD for the patient who is actually to be treated,
2 e.g. via an estimation within the judgment of the physician, typically with consideration given to
3 the patient's history and teachings in the relevant field, although the MTD is more usually
4 defined by reference to other patients who have a similar disease profile. The actual MTD for
5 the specific patient under treatment, for obvious reasons, is difficult to establish in a de novo
6 patient since the goals of establishing the specific MTD for the patient and treating the patient
7 with a patient-specific optimally effective dose may be at odds.

8 Once the patient subpopulation is defined, the MTD is established, typically through a
9 dose escalation study. For example, the MTD was established as a 75 cGy total body dose for
10 chemotherapy relapsed/refractory patients with non-Hodgkin's lymphoma (Kaminski, M.S. et
11 al., "Iodine-131-Anti-B1 Radioimmunotherapy for B-cell Lymphoma," J. Clin. Oncol., 14:1974-
12 1981 (1996)). Thus, in the methods of the invention, the step of determining the MTD may
13 comprise performing a dose escalation study for the radiopharmaceutical in a patient
14 subpopulation.

15 The MTD may be set differently for different patient groups, or the value may be
16 considered a different desired total body dose (TBD), discussed in further detail below, for a
17 particular patient subgroup. For example, a dose of 75 cGy to the whole body may be
18 established in a given patient population (e.g., all patients with non-Hodgkin's lymphoma who
19 are refractory to chemotherapy) as the MTD via a dose escalation study, but then be attenuated
20 for a patient with low platelet counts to 65 cGy. Thus, the 65cGy may be considered the desired
21 TBD for a patient within a subgroup of the population (e.g., all patients with non-Hodgkin's
22 lymphoma who are refractory to chemotherapy and who have low platelet count). Alternatively,
23 the MTD may be established, as by a separate dose escalation study, in a population of patients
24 that is defined as all patients with non-Hodgkin's lymphoma who are refractory to chemotherapy
25 and who have low platelet counts. Then, a particular patient may have a desired TBD equal to
26 the MTD. In any case, it is evident that TBD/MTD represents an attenuation factor that is
27 preferably multiplied by the activity hours/residence time for the particular patient to be treated
28 with the radiopharmaceutical.

1 **Total Body Dose**

2 The desired TBD is determined for the patient and may be based on information on the
3 patient population or subpopulation or it may be specific to the individual patient, within the
4 judgment of the physician. The value for TBD is generally equal to or lesser than the MTD.

5 Measurement of the clearance rate and determination of the desired TBD for treatment of
6 the patient is a more significant predictor of toxicity and appropriate therapeutic dose than the
7 patient's body weight or surface area. Thus, calculation of an actual mCi amount of therapeutic
8 dose for the patient, with a variety of patient-specific factors taken into account, is more potent
9 than simply performing a mCi/kg or mCi/m² calculation.

10 Whole body dosimetry, which focuses on the absorbed dose in the whole body of the
11 patient, is a simpler and more appropriate focus than organ dosimetry. It is an accurate, precise,
12 and reproducible approach to treatment of the patient. Organ dosimetry, on the other hand,
13 requires multiple views, the often highly subjective practice of drawing of regions of interest
14 around organs, estimates of organ volume, calculation of fractional energy deposition in organs,
15 difficult to correct background counts, attenuation correction, and scatter correction.

16 Even though the bone marrow may be the expected target organ for radiation-induced
17 toxicity of a particular radiopharmaceutical, it is feasible to focus the data acquisition on the
18 whole body of the patient. Bone marrow dosimetric estimates are generally difficult to obtain,
19 especially if there are any malignant cells admixed with the normal bone marrow elements.
20 Although bone marrow dosimetry calculations from gamma scans have been performed, they are
21 particularly challenging in patients with high-bulk lymphoma, as the lymphoma often involves
22 the lymph nodes overlying marrow, making planar imaging-based estimation of bone marrow
23 dose difficult or impossible. While precisely quantitated single photon emission computed
24 tomography (SPECT) images may address this, the methods of the invention, focused on the
25 whole body of the patient, provides the necessary data for a reliably optimized therapeutic dose.

26 The whole body dosimetry approach of the invention is based on a model that assumes
27 the radiopharmaceutical is distributed uniformly throughout the patient's lean body portion
28 following administration and remains so. This homogeneous model is clearly a simpler and more
29 workable model than heterogeneous models, as it requires only a single whole body radiation
30 activity input value per time point making it extremely suitable for a prospective dosimetric
31 method.

Clearance Profile

Information on the clearance profile, or usual pattern of clearance, of the radiopharmaceutical from humans to whom it has been administered is useful in the methods of the invention. Specifically, the clearance profile of the radiopharmaceutical indicates whether the radiopharmaceutical clears in a generally straight line, i.e. according to a monoexponential profile, or whether the radiopharmaceutical clears according a more complicated pattern. "Clearing" or "clearance" of the radiopharmaceutical as used herein refers to the process of diminishment of radioactivity within the patient's body over time, whether through normal physiological functions, such as elimination of the radiopharmaceutical from the body, or natural decay of the radionuclide.

Knowledge of the typical clearance profile for the radiopharmaceutical is useful to determine, e.g. if the radiopharmaceutical clears according to a monoexponential profile (with one slope, basically a straight line), a biexponential profile (two slopes), a triexponential profile (three slopes), etc. This information becomes useful in determining how many data points should be gathered for a high degree of confidence at the step of determining the residence time of the radiopharmaceutical. In other words, one can more accurately gauge the appropriate, usually the minimum feasible, number of data points if the usual clearance profile of the radiopharmaceutical or its analog is known. Two to three data points per exponential term are generally sufficient. If there is monoexponential clearance, for example, 2-3 data points may be sufficient for a high degree of confidence in the resulting calculations. For a radiopharmaceutical that clears biexponentially, measurement at 4-6 data points is preferred. For a radiopharmaceutical that clears triexponentially, measurement at 6-9 data points is preferred. Although data may be gathered at a higher number of points, it is convenient to know the minimum number recommended for an acceptable level of confidence in the results.

If clearance profile information for the radiopharmaceutical is unavailable, one may calculate a therapeutic dose for the patient by assuming that the radiopharmaceutical clears in a monoexponential pattern, given the fact that a majority of radiopharmaceuticals clear in this manner. It is preferable to get an actual clearance profile of the radiopharmaceutical, however, for greatest confidence in the results.

1 The clearance profile may be dependent on a number of factors including the specificity
2 and affinity of the radiopharmaceutical to its target, the size of the radiopharmaceutical, and the
3 species of origin (e.g., a murine antibody given to a human patient will clear differently than a
4 human or humanized antibody will clear in the human patient).

5 The step of determining the clearance profile may comprise performing a simple study of
6 the radiopharmaceutical in a given patient subpopulation, such as administration of the
7 radiopharmaceutical followed by simple measurement over time of the loss of radioactivity.
8 Although determination of the clearance profile in humans is preferred, clearance profile
9 information gathered from an animal model is also useful. A dose escalation study, such as that
10 described above with reference to establishing an MTD, is also useful for an indication of the
11 clearance profile of the radiopharmaceutical of interest. Further, the usefulness of an
12 radiopharmaceutical analog was discussed above with reference to the dosimetric evaluation of
13 the individual patient. Similarly, an analog of the radiopharmaceutical may be used to determine
14 the clearance profile.

15 It should be understood that "clearance profile" as used herein refers to a general
16 characteristic of the radiopharmaceutical in patients, i.e., the shape of the activity-time curve.
17 This is distinct from the step of determining the residence time, discussed below, which refers to
18 the time the activity of the radiopharmaceutical remains *in the individual patient*. Thus, the step
19 of determining the residence time incorporates the concept of measuring the clearance rate of the
20 radiopharmaceutical or its analog in the individual patient, whereas the step of determining the
21 clearance profile is generally based on information gathered from other than the individual
22 patient.

23 Although "determining" has been used in reference to the step of utilizing the clearance
24 profile of the radiopharmaceutical, it will be evident that such data may be gathered from
25 historical sources, such as published literature or other knowledge available to one of skill in the
26 relevant field, and not just by actually performing the step of establishing the clearance profile at
27 the time that the individual patient's needs are addressed. Thus, one may have determined the
28 clearance profile of the radiopharmaceutical by reference to published data *from a prior time* and
29 then *presently* be utilizing such information in the method of establishing the optimal patient-
30 specific dose for treatment of the patient. There is no requirement in the methods of the
31 invention of *timing* of the step of determining the clearance profile; i.e., no requirement of when

1 or by whom the clearance profile is determined. Similarly, there are no such limitations on the
2 steps of determining a maximum tolerated dose and a desired total body dose for the
3 radiopharmaceutical.

5 **Maximum Effective Mass**

6 Preferably, the methods of the present invention take into account any adjustments that
7 may be necessary due to obesity of the patient. The concept of focusing on the patient's lean
8 body mass or maximum effective mass (MEM) represents a departure from the usual approaches
9 to dosimetry and is based on the theory that the human body represents two major compartments,
10 a "fat" compartment and a "lean" compartment residing within the fat compartment.

11 Distribution of the radiopharmaceutical is not uniform throughout the patient's body. Little
12 accumulation of the radiopharmaceutical actually occurs in the fat compartment. The bone
13 marrow, which is especially susceptible to toxicities related to treatment with
14 radiopharmaceuticals, is part of the lean compartment, according to this theory. Thus, if a
15 patient, and especially an obese patient, is dosed simply based on mass, e.g. on a mCi/kg basis,
16 then there is the potential for overdosing the patient and ablating the bone marrow. A more
17 appropriate model is that the radioactivity is distributed uniformly mostly within the lean
18 component of the patient's body.

19 **Figure 1** illustrates the relationship of the fat and lean components of the individual
20 patient, generally represented as superimposed ellipsoids. The outer ellipsoid, with the larger x
21 and y dimensions, represents fat plus lean body mass. The inner ellipsoid with the same aspect
22 ratios, is defined (in kg), where height is measured in centimeters, by the following formulae:

23 Males: $48.0 + 1.06(\text{height}-152) = \text{Lean Body Mass}$

24 Females: $45.5 + 0.91(\text{height}-152) = \text{Lean Body Mass}.$

25
26 It is understood that lean body mass may also be directly measured by computerized
27 tomography, x-ray absorptiometry, immersion weighing, and other known methods. The total
28 body absorbed dose is then determined for the lean body ellipsoid, assuming the MTD was
29 established for the lean body mass. Corrections for Compton scatter of photons from the fat
30 compartment or some trace accumulation in the fat compartment are also possible (e.g., Monte

Carlo simulations of radiation scatter and reabsorption may be performed for the fat and lean components), but need not be included in the simplest calculation of the lean body mass.

It follows that a calculation of the portion of the patient which is "lean body mass" should be used for an accurate determination of the appropriate dose to be given to the patient at the treatment stage. Alternatively, the patient's MEM may be determined, for this purpose. In the case of one particular radiopharmaceutical, the MEM was defined as 1.37 times the lean body mass, based on empirical data gathered from dose escalation studies in the patient population. A fair approximation of the MEM for treatment purposes with the particular radiopharmaceutical may then be generated from the given formulas (with the slight modification of $1.37 \times$ lean body mass) and put in tabular form, as seen in **Table 1**, for example, or may be incorporated into a software program. Once the table is generated for the particular radiopharmaceutical, one need not calculate the lean body mass for each patient, but instead may refer to the table, taking the patient's gender and height into account, to find the MEM and then use the lower of the actual mass (M) of the patient or the MEM in further calculations.

Table 1
Maximum Effective Mass for ^{131}I -Labeled Anti-B1 Radiopharmaceutical

Men			Women		
Height (ft, in)	Height (cm)	Maximum Effective Mass (kg)	Height (ft, in)	Height (cm)	Maximum Effective Mass (kg)
4'5"	134.5	40.5	4'5"	134.5	40.7
4'6"	137.0	44.2	4'6"	137.0	43.8
4'7"	140.0	47.9	4'7"	140.0	47.0
4'8"	142.0	51.6	4'8"	142.0	50.2
4'9"	145.0	55.3	4'9"	145.0	53.3
4'10"	147.5	59.0	4'10"	147.5	56.5
4'11"	150.0	62.7	4'11"	150.0	59.7
5'0"	152.5	66.3	5'0"	152.5	62.8
5'1"	155.0	70.0	5'1"	155.0	66.0
5'2"	157.5	73.7	5'2"	157.5	69.2
5'3"	160.0	77.4	5'3"	160.0	72.3
5'4"	162.5	81.1	5'4"	162.5	75.5
5'5"	165.0	84.8	5'5"	165.0	78.7
5'6"	167.5	88.5	5'6"	167.5	81.8

5'7"	170.0	92.2		5'7"	170.0	85.0
5'8"	172.5	95.8		5'8"	172.5	88.2
5'9"	175.5	99.5		5'9"	175.5	91.3
5'10"	178.0	103.2		5'10"	178.0	94.5
5'11"	180.5	106.9		5'11"	180.5	97.7
6'0"	183.0	110.6		6'0"	183.0	100.8
6'1"	185.5	114.3		6'1"	185.5	104.0
6'2"	188.0	118.0		6'2"	188.0	107.2
6'3"	190.5	121.7		6'3"	190.5	110.3
6'4"	193.0	125.4		6'4"	193.0	113.5
6'5"	195.5	129.0		6'5"	195.5	116.7
6'6"	198.0	132.7		6'6"	198.0	119.8
6'7"	200.5	136.4		6'7"	200.5	123.0
6'8"	203.0	140.0		6'8"	203.0	126.2
6'9"	205.5	143.8		6'9"	205.5	129.3
6'10"	208.5	147.5		6'10"	208.5	132.5
6'11"	211.0	151.2		6'11"	211.0	135.7
7'0"	213.5	154.9		7'0"	213.5	138.8

Multiply lb by 0.454 to determine kg. Multiply in by 2.54 to determine cm. To calculate the maximum effective mass for patient heights not included in above table use the following formulas (18):

$$\text{Men: MEM (kg) = 65.76 + 1.452 (ht in cm - 152)}$$

$$\text{Women: MEM (kg) = 62.34 + 1.247 (ht in cm - 152).}$$

Thus, the lean body mass or MEM of the patient is preferably determined to account for the nonhomogeneous biodistribution of radioactivity in obese patients. Patients weighing in excess of the maximum effective mass may then be treated with a dose of the radiopharmaceutical calculated based on the maximum effective mass. Patients having a mass less than the determined maximum effective mass may have their therapeutic dose calculated based on their actual body mass. By first estimating what fraction of the body is lean and then calculating the radioactivity distribution within a given body mass, the proper dose of radiopharmaceutical for treatment without undue toxicity can be administered on an individualized, case-by-case basis.

Activity Hours

Once the patient's maximum effective mass is determined, e.g. through the use of the information provided in Table 1, then the lower of the patient's M or MEM is used in the

determination of the activity hours to deliver the desired total body dose.

The activity hours (“AH” in the equation), also known as cumulated activity, for the radiopharmaceutical are determined based on a combination of patient-specific factors (such as the M or MEM and the desired TBD) and general characteristics of the radionuclide. The AH is measured in units of millicurie hours (mCi • hr) and is defined by Equation I as follows:

$$AH = \frac{TBD \times (M \text{ or } MEM)}{\left[\sum_{elec} \Delta_{elect} + \sum_{phot} \Delta_{phot} \phi_{phot}^{TB} \right]}$$

(Equation I).

The bracketed portion of the equation represents the sum of electron energy plus photon energy deposited in the patient’s total body and will vary depending on the radionuclide used and the patient’s mass. Thus, for each radionuclide, using the equation above along with published data, such as that obtained from MIRD pamphlets, one can generate tables or create databases that are dependent on the radionuclide and the patient and, and which will provide an indication of the activity hours needed to deliver a desired total body dose to the patient. This avoids the need to do repeated calculations.

For example, if it is known that 75 cGy of a particular ¹³¹I-labeled antibody is of therapeutic value, one can substitute 75 cGy for the total body dose (TBD) in the equation above, generate the bracketed portion of the equation based on characteristics of the patient and the particular radionuclide, in this case ¹³¹I, and simply need to input the individual patient’s M or MEM to determine the activity hours needed to obtain the desired TBD.

Equation I is simply the desired TBD (i.e., 75 cGy) divided by the total body S-value since the total body S-value (as opposed to organ-specific S-value) for the patient is the bracketed term in Equation I divided by the M or MEM. The S-value is the absorbed dose per unit cumulated activity. S-values calculated using this approach are based on the actual patient M or MEM rather than using a standardized mass of some anthropomorphic model. Thus, these S-values, and therefore the activity hours, are patient-specific. Notably, the patient-specific residence time, discussed in detail below, multiplied by the total body S-value, gives the therapeutic dose in units of cGy/mCi.

Table 2 is an example of a look-up table for determining the activity hours needed to deliver a dose of 75 cGy of ^{131}I to the whole body of the patient, based on the patient's M or MEM. The values in Table 2 were generated with the aid of published data. Specifically, assuming that the patient is "ellipsoid" in shape, absorbed fractions of ^{131}I photon energy deposited in an ellipsoid of principal axes ratios of 1/1.8/9.27 for various masses were calculated from Medical Internal Radiation Dose (MIRD) Pamphlet No. 3, Table 9 (Brownell, G.L., et al., *Absorbed fractions for photon dosimetry*, Soc. Nucl. Med.; MIRD Pamphlet No. 3: Table 9 (1968)) and the mean energy emitted per nuclear transition was obtained from the ^{131}I decay scheme data in MIRD Pamphlet No. 10 (Dillman, L.T., et al., *Radionuclide decay schemes and nuclear parameters for use in radiation-dose estimation*, Soc. Nucl. Med., MIRD Pamphlet No. 10 (1975)). The total body S-values using these two parameters and this approach for a wide range of patient masses were compared to S-values from the MIRDose 3.1 program and showed very close agreement over a wide range of patient total body masses. It is evident that one may also, or alternatively, generate a table of S-values (cGy/mCi·hr) rather than activity hours, which would not have information on the patient's TBD. An adjustment to account for the patient's TBD could easily be made once the appropriate S-value is determined for treatment of the patient. Similarly, one may wish to generate a table of activity hours or S-values based on the Δ_{elect} , Δ_{phot} , and ϕ_{phot}^{TB} values using a different model for the particular radionuclide. In particular situations, the tables may be eliminated altogether and only the patient's M or MEM may be used since, e.g., for ^{131}I the activity hours are a slowly varying function of mass. It is possible to multiply the patient's M or MEM by AH/kg or an AH/kg function (obtained from analysis of the AH/kg vs. kg curve).

TABLE 2
Activity Hours to Deliver a 75 cGy Total Body Radiation Dose of ^{131}I

M or MEM ¹ (kg)	Activity Hours (mCi hr)	M or MEM ¹ (kg)	Activity Hours (mCi hr)	M or MEM ¹ (kg)	Activity Hours (mCi hr)	M or MEM ¹ (kg)	Activity Hours (mCi hr)	M or MEM ¹ (kg)	Activity Hours (mCi hr)
40.0	4638	60.0	6686	80.0	8670	100.0	10595	120.0	12463
40.5	4690	60.5	6737	80.5	8718	100.5	10643	120.5	12509
41.0	4743	61.0	6787	81.0	8767	101.0	10690	121.0	12556

41.5	4796	61.5	6838	81.5	8816	101.5	10738	121.5	12602
42.0	4848	62.0	6888	82.0	8864	102.0	10785	122.0	12648
42.5	4901	62.5	6938	82.5	8913	102.5	10833	122.5	12694
43.0	4953	63.0	6989	83.0	8961	103.0	10880	123.0	12741
43.5	5005	63.5	7039	83.5	9010	103.5	10927	123.5	12787
44.0	5057	64.0	7089	84.0	9058	104.0	10975	124.0	12833
44.5	5109	64.5	7139	84.5	9106	104.5	11022	124.5	12879
45.0	5160	65.0	7189	85.0	9154	105.0	11069	125.0	12925
45.5	5212	65.5	7238	85.5	9202	105.5	11116	125.5	12971
46.0	5264	66.0	7288	86.0	9251	106.0	11163	126.0	13017
46.5	5315	66.5	7338	86.5	9299	106.5	11210	126.5	13063
47.0	5366	67.0	7387	87.0	9347	107.0	11257	127.0	13109
47.5	5413	67.5	7437	87.5	9394	107.5	11304	127.5	13155
48.0	5469	68.0	7486	88.0	9442	108.0	11351	128.0	13200
48.5	5520	68.5	7536	88.5	9490	108.5	11398	128.5	13246
49.0	5571	69.0	7585	89.0	9538	109.0	11445	129.0	13292
49.5	5621	69.5	7634	89.5	9585	109.5	11492	129.5	13337
50.0	5672	70.0	7683	90.0	9633	110.0	11538	130.0	13383
50.5	5724	70.5	7733	90.5	9682	110.5	11585	130.5	13429
51.0	5775	71.0	7783	91.0	9730	111.0	11632	131.0	13474
51.5	5826	71.5	7833	91.5	9779	111.5	11678	131.5	13520
52.0 ¹	5878	72.0	7883	92.0	9827	112.0	11725	132.0	13565
52.5	5929	72.5	7932	92.5	9875	112.5	11771	132.5	13611
53.0	5980	73.0	7982	93.0	9924	113.0	11818	133.0	13656
53.5	6031	73.5	8031	93.5	9972	113.5	11864	133.5	13701
54.0	6082	74.0	8081	94.0	10020	114.0	11910	134.0	13747
54.5	6133	74.5	8130	94.5	10068	114.5	11957	134.5	13792
55.0	6184	75.0	8180	95.0	10117	115.0	12003	135.0	13837
55.5	6234	75.5	8229	95.5	10165	115.5	12049	135.5	13882
56.0	6285	76.0	8278	96.0	10213	116.0	12095	136.0	13928
56.5	6335	76.5	8327	96.5	10261	116.5	12141	136.5	13973
57.0	6386	77.0	8376	97.0	10309	117.0	12187	137.0	14018
57.5	6436	77.5	8425	97.5	10357	117.5	12233	137.5	14063
58.0	6486	78.0	8474	98.0	10404	118.0	12279	138.0	14108
58.5	6536	78.5	8523	98.5	10452	118.5	12325	138.5	14153
59.0	6586	79.0	8572	99.0	10500	119.0	12371	139.0	14198
59.5	6636	79.5	8621	99.5	10548	119.5	12417	139.5	14242

¹ Minimum of the patient's actual mass (M) (kg) or maximum effective mass (MEM) (kg). For values between 140 kg and 160 kg use the following formula:

$$\text{Activity hours (mCi hr)} = 14287 + (88.74) (\text{mass in kg} - 140).$$

For patients below 40 kg or above 160 kg, Equation I may be applied, with an appropriate adjustment for ϕ^{TB}_{phot} .

If one is consistently using the methods of the present invention to tailor a patient-specific therapeutic dose for a particular radiopharmaceutical and the desired TBD for all of the

1 patients to be treated is also consistent, then a look-up table, such as **Table 2**, set for the
2 particular radiopharmaceutical and desired TBD, is a useful tool in the practice of the invention.
3 Alternatively, one can easily put the information regarding the activity hours needed to deliver
4 any desired TBD of a particular radionuclide to a patient into a database, so that only the
5 patient's M or MEM and the desired TBD need to be entered into a software program designed
6 to access the database, to generate the number of needed activity hours. The use of software and
7 the generation of databases on activity hours are especially advantageous if one is working with
8 several different radionuclides or several different desired total body doses, and a variety of
9 patient masses.

11 **Dosimetric Evaluation**

12 Since it is difficult to predict exactly how an individual patient will react to the
13 radiopharmaceutical, a dosimetric evaluation is performed to calculate the appropriate amount of
14 the therapeutic dose of the radiopharmaceutical.

15 Dosimetric evaluation is generally useful for measuring biodistribution and looking at
16 localization of the radiopharmaceutical within the body of the patient. Primarily, however, its
17 value in the methods of the present invention is for measuring the rate of clearance, particularly
18 the residence time, of the radiopharmaceutical in the total body of the individual patient.
19 Although the typical clearance profile for the radiopharmaceutical is preferably known at the
20 time of treating the individual patient, the rate of clearance of the radiopharmaceutical is specific
21 to the individual patient.

22 Generally, a tracer dose of the radiopharmaceutical, labeled with an amount of the
23 radionuclide sufficient to gather imaging or count data, but not necessarily of a therapeutic level,
24 is given to the patient at the dosimetric evaluation stage. Thus, an ^{131}I -labeled
25 radiopharmaceutical of 0.5-10 mCi may be used at the dosimetric stage and the same ^{131}I -labeled
26 radiopharmaceutical may be used at a dose of 10-400 mCi for treatment of the patient for
27 disease. Although the radiopharmaceutical to be used at the therapeutic stage may be used at the
28 dosimetric stage, a suitable analog may also be used within the judgment of those of skill in the
29 art. For example, the therapeutic radiopharmaceutical may be an ^{90}Y -labeled monoclonal
30 antibody and the radiopharmaceutical analog suitable as a tracer for dosimetric evaluation may
31 be an ^{111}In -labeled version of the same monoclonal antibody.

1 The tracer is preferably administered to the patient intravenously, although other means
2 for administering pharmaceuticals to patients may be used.

4 **Imaging**

5 The type of emissions from the radionuclide portion of the radiopharmaceutical will
6 determine the best means for imaging the tracer at the dosimetric evaluation stage. For example,
7 ^{131}I is a combined beta and gamma particle emitter. The gamma photons from ^{131}I decay,
8 although of high energy, are easily detectable by gamma scintigraphy or thyroid probe. Since
9 ^{90}Y is primarily a beta emitter, either an analog (such as an ^{111}In -labeled version of the
10 radiopharmaceutical) can be used at the dosimetric stage, as discussed above, or a properly
11 calibrated instrument suitable for the radionuclide, such as a gamma camera or thyroid probe that
12 measures Bremsstrahlung emissions of ^{90}Y , may be used.

13 More typically, however, a probe, such as a collimated sodium iodide probe (for example,
14 Picker Model 1 thyroid probe) is useful for obtaining information for the dosimetric evaluation.
15 Alternatively, a gamma camera having either a single-head or dual-head configuration may be
16 used. Both methods appear to be suitable for determining the rate of total body clearance of the
17 tracer and comparable results have been obtained.

18 The gamma camera is equipped with a collimator suitable for the radionuclide. In the case
19 of an ^{131}I -labeled radiopharmaceutical, the gamma camera is preferably a large or an extra large
20 field of view and is equipped with a medium- or high-energy parallel hole collimator suitable for
21 performing whole body scans and whole body counts. While patient-specific total body
22 dosimetry may be performed by whole body camera passes or probe measurements,
23 consideration should be given to using a conjugate view probe approach in each patient as it
24 generally requires less time. For example, anterior and posterior probe counts may take only two
25 minutes for image acquisition per data point whereas gamma camera whole body passes may
26 require twenty minutes. In many cases, however, the use of anterior *or* posterior (or lateral or
27 oblique) body counts may be sufficient for a high degree of confidence, so that a conjugate view
28 is not strictly necessary.

29 It is important to note that "imaging" as used herein, denotes any activity that allows for
30 the gathering of counting data on the tracer. An actual visual image, while often desirable for
31 following the localization of the radiopharmaceutical, is not strictly necessary. Thus, "imaging"

1 for the purpose of carrying out the methods of the invention includes the use of equipment which
2 provides data of a primarily numeric value, as well as that which provides visual images.
3 Further, imaging includes gathering data on the clearance profile of the radiopharmaceutical via
4 blood or urine sampling at the various time points and counting the radioactivity of the samples,
5 e.g. via a calibrated well counter or a liquid scintillation counter.

6 Quality control of the equipment is important. Further, images of the same duration
7 should be made at each time point of the dosimetric evaluation, preferably using the same
8 camera, collimator, and other equipment. Thus, camera and probe sensitivity should ideally be
9 checked each day prior to obtaining the patient whole body counts. A liquid or solid source of a
10 calibrated amount of the radionuclide is preferably scanned to determine the counting efficiency
11 (background corrected CPM/ μ Ci). This step assures that the probe or camera parameters, such
12 as the same collimator, scanning speed, window setting, and geometry, are maintained at each
13 imaging time point.

14 15 **Residence Time**

16 An understanding of the amount of time that the radiopharmaceutical remains within the
17 patient's body to provide a therapeutic, but not unduly toxic, effect is important to optimal
18 dosing. Radiopharmaceuticals clear from the human body at different rates based on the
19 individual's unique physiological characteristics. In fact, the inventors of the dosimetry
20 approach taught herein have found that patients of similar size may have a two- to five-fold
21 difference in clearance rate. Thus, it is highly advantageous to perform a dosimetric evaluation
22 on the patient prior to therapy with the radiopharmaceutical. Dosimetric evaluation with the
23 radiopharmaceutical (usually a dose having a smaller amount of radioactivity) or an appropriate
24 analog thereof determines the individual patient's residence time for use in calculation of the
25 therapeutic dose of the radiopharmaceutical yet to be administered.

26 The time course of radioactivity clearance in the patient of an administered dosimetric or
27 tracer dose of the radiopharmaceutical or of a radiopharmaceutical analog is followed via the
28 pre-therapy dosimetric evaluation. Typically, a lower millicurie amount of the
29 radiopharmaceutical than will actually be administered at a therapeutic stage is administered to
30 the patient during the dosimetric evaluation, then the level of radioactivity within the patient is
31 measured by means of imaging to determine the percent injected activity at the first time point.

1 This is followed by measurement of the percent injected activity at later time points for
2 elucidation of the clearance rate of the radiopharmaceutical in the individual patient. As can be
3 expected, the percent injected activity is approximately 100% at the first time point, or it may be
4 normalized to 100%. Information on the radioactivity (i.e., counting data) within the patient's
5 body at later time points is then adjusted with reference to the first time point, so that each later
6 time point is a percentage of the first time point. For greater accuracy, each measured time point
7 is preferably background corrected so that radioactivity levels in the environment not originating
8 from the patient may be eliminated from consideration.

9 More specifically, to determine the residence time in hours, the patient is administered the
10 dosimetric dose, typically via intravenous infusion, on Day 0. At time point 1, usually within a
11 reasonable time, such as one hour, after infusion of the radiopharmaceutical or analog, and
12 before the patient excretes the radioactivity, radioactivity counts are obtained via imaging. Time
13 point 1 is actually calculated from the start of the infusion to the time of image acquisition on
14 Day 0.

15 The background corrected total body count at the time point (defined as the geometric
16 mean of the anterior and posterior counts after the respective background counts have been
17 subtracted) is then calculated as follows:

$$18 \quad \text{Background corrected count} = \sqrt{(C_A - C_{BA})(C_P - C_{BP})}$$

19 (Equation II).

20 In this equation, C_A = the anterior counts, C_{BA} = the anterior background counts. C_P = the
21 posterior counts, and C_{BP} = the posterior background counts. It is notable that counts obtained
22 from only a single projection per time point generally result in equivalent residence times as
23 those obtained from conjugate anterior and posterior images. Therefore, for single head cameras,
24 total body residence times may be calculated using only anterior counts. In the equation above,
25 therefore, only the anterior background corrected counts ($C_A - C_{BA}$) would be used.

26 Imaging or radioactivity count acquisition is repeated at the later time points in the same
27 manner. The total number and frequency of the data points is dependent on the anticipated
28 clearance profile, e.g. ^{131}I -anti-B1 clears in a monoexponential pattern considering both
29 elimination and the physical decay of the radionuclide. Thus, for a particular ^{131}I -labeled
30 radiopharmaceutical, for example, data was gathered at three time points, Day 0, Day 2, 3, or 4,

1 and Day 6 or 7. These time points were selected as appropriate because the radiopharmaceutical
2 had a monoexponential clearance profile (so data acquisition at three time points is within sound
3 judgment) and a physical half-life of 8 days (so measurements are properly spaced at
4 approximately time zero, a time close to the physical half-life, and an intermediate time). As
5 discussed above with respect to gathering information on the typical clearance profile of the
6 radiopharmaceutical, correlation of the number of time points to the clearance pattern is
7 preferred so that at least 2 time point measurements are made if the radiopharmaceutical has
8 monoexponential clearance, at least 4 time point measurements are made if the
9 radioimmunoconjugate has biexponential clearance, and at least 6 measurements are made if the
10 radioimmunoconjugate has triexponential clearance, etc. Of course, the recommended number
11 and frequency of data points to obtain a calculated therapeutic dose for the particular
12 radiopharmaceutical with a high degree of confidence may be adjusted within the judgment of
13 the physician or other health care personnel on a case-by-case basis.

14 According to a graphical method of determining the residence time, the percent injected
15 activity remaining for each time point is then calculated by dividing the background corrected
16 total body count from that time point by the count from Day 0 and multiplying by 100. The
17 residence time in hours is then determined by plotting the time from the start of the infusion and
18 the percent injected activity values for the later time points on a semi-log graph (as in **Figure 7**).
19 A best-fit line is then drawn, originating from 100% (the Day 0 value) that best fit the other
20 plotted points. If the line does not intersect all the data points, one point should fall above the
21 best-fit line and the other point should fall below the best-fit line. The residence time in hours is
22 then read from the x-axis of the graph at the point where the fitted line intersects the horizontal
23 37% injected activity line, since by definition the residence time for a radionuclide with a
24 monoexponential clearance pattern is equal to the time at which the percent injected activity is
25 37%. Even though calculation of the percent injected activity at each time point is preferred, an
26 activity-time curve may be generated by using the raw counts at each time point or the actual
27 activity obtained from the raw counts.

28 Mathematically, the residence time (τ) is given by

$$\tau = \frac{1}{\text{slope}} = 1.443 T_{eff}$$

where T_{eff} is the effective half-life of the radionuclide. It should be noted that the individual patient's total body effective half-life, or T_{eff} , is quite distinct from the physical half-life of the radiopharmaceutical or, more specifically, the physical decay of the radionuclide. The T_{eff} is related to the physical half-life (T_p) and the biological half-life (T_b) of the radiopharmaceutical as follows: $T_{\text{eff}} = (T_p \times T_b) / (T_p + T_b)$.

Alternatively or additionally, the residence time may be determined by substituting the times from infusions of the later data points, (t_2 and t_3 in the example below) and the background corrected counts of each data point (C_1 , C_2 , and C_3 in the example) in the following equation:

$$\text{Residence time (hr)} = \frac{t_2 (1 - \frac{C_2}{C_1})}{\log_e (\frac{C_1}{C_2})} + \frac{\frac{C_2}{C_1} (t_3 - t_2)}{\log_e (\frac{C_2}{C_3})}$$

(Equation III).

The natural logarithm is denoted by \log_e . The formula uses log-linear interpolation over the time spanned by the data acquisition and two point log-linear extrapolation. The formula may be adjusted if additional data points are collected.

Calculation of the residence time may also be effected by using a software program to fit the percent injected activity versus time curve using the standard method of nonlinear least squares using all data points. The data are fit to the function

$$\sum_{i=1}^n a_i e^{-\alpha_i t} \quad (\text{Equation IV})$$

where the a 's are the intercepts and the α 's are the slopes. In the equation, n is the number of exponential terms. Therefore, for a monoexponential function, there is one slope and one intercept and the residence time is equal to $1/\alpha$ or $1/\text{slope}$, when plotted on a log-linear graph with percent injected activity plotted on the y-axis and time on the x-axis. For a biexponential function, there are two slopes and two intercepts and the residence time is equal to

$$\frac{a_1 / \alpha_1 + a_2 / \alpha_2}{a_1 + a_2} \text{ when similarly plotted.}$$

In the same manner, the residence time can be calculated for a radiopharmaceutical with a triexponential clearance pattern, etc. The residence time (τ) is then obtained as follows:

$$\tau = \frac{\sum_{i=1}^n \frac{a_i}{\alpha_i}}{\sum_{i=1}^n a_i} \quad (\text{Equation V}).$$

where a_i are the intercepts and α_i are the slopes of the i th exponential term.

Further, several methods are available for determining residence time from graphical representations of the activity-time curve. Among these are numerical methods such as the trapezoidal rule (Bers, L., Calculus, Holt, Rineholt, and Winston, Inc., New York, pp. 413-416 (1969)), Simpson's rule (Macon, N., Numerical Analysis, Wiley, New York (1963)), and analytical methods based on the assumption that some fitting function can adequately describe the data (Riggs, D.S., The Mathematical Approach to Physiological Problems, MIT Press, Cambridge, Mass.(1976)).

Determination of the residence time of the radiopharmaceutical or analog thereof in the individual patient's body may therefore be made through (i) the use of the graphical method, (ii) the use of Equation III, or (iii) via a least squares fit or another curve-fitting program to the percent injected activity versus time curve according to Equation V, or some other method.

Furthermore, it is understood that data acquisition and calculation of the residence time for the patient may be efficiently performed through the use of an appropriate software program. For example, the software program is developed to determine the percent injected activity versus time curve and then fit these data using the standard method of nonlinear least squares using all data points, and perform the residence time calculation according to Equation V. Alternatively or additionally, software programs utilizing Equation III or the graphical method of calculating residence time (with or without a graphical display for the user) may also be developed. Preferably, the program is tailored to the particular radiopharmaceutical so that minimal input is needed to perform rapid calculations for each specific patient.

Thus, the step of determining the residence time for the radiopharmaceutical therefore usually comprises making measurements of percent injected activity of the radiopharmaceutical at each of a number of time points, the number of time points being correlated to the clearance pattern of the radiopharmaceutical, and then determining the residence time.

1 There should be good correlation of the dosimetric prediction of residence time with the
2 actual residence time measured after administration of the therapeutic dose for the
3 radiopharmaceutical. Generally, the therapeutic dose should be given within a reasonable
4 amount of time after the dosimetric evaluation. If a substantial amount of time has passed,
5 performance of another dosimetric evaluation is preferred to account for factors such as disease
6 progression, human anti-mouse antibody (HAMA) responses, etc. In other words, the patient
7 may have more disease, less disease, or have developed resistance to the antibody portion of the
8 radiopharmaceutical at the time of treatment as compared to the time of the original dosimetric
9 evaluation. Therefore, another dosimetric evaluation to obtain the residence time of the
10 radiopharmaceutical in the whole body of the patient is recommended before actually treating the
11 patient.

12 13 **Calculation of the Patient-Specific Optimally Effective Dose**

14 The patient-specific administered activity for therapy is calculated using the patient-
15 specific total body residence time and the activity hours required to deliver a specified TBD to
16 the patient, optionally multiplied by an attenuation factor. The following equation may be used
17 to calculate the therapeutic dose (mCi) of the radiopharmaceutical:

$$18 \quad \text{Therapeutic Dose (mCi)} = \frac{\text{Activity hours (mCi hr)}}{\text{Residence time (hr)}} \times \frac{\text{Desired TBD (cGy)}}{\text{MTD cGy}}$$

19 (Equation VI).

20 One can solve for the appropriate therapeutic dose to be given to the individual patient by
21 substituting in the various factors in the equation. As discussed above, most of the various
22 factors are themselves patient-specific. The radiopharmaceutical therapy dose for an individual
23 patient is determined from that individual's lean body mass, or M or MEM, and not the 70 kg
24 average for men or the 56 kg average for women commonly used. Treatment can thus be
25 tailored to the patient's size and the patient's pharmacokinetics.

26 A method of establishing a patient-specific optimally effective dose for administration of
27 a radiopharmaceutical to a patient for treatment may therefore be thought of as comprising the
28 following steps, although performing the steps in strict order as presented below is not necessary:
29 determining a maximum tolerated dose for the radiopharmaceutical (usually by reference
30 to the relevant patient subpopulation),

1 determining a desired total body dose of the radiopharmaceutical for the patient,
2 determining the clearance profile for the radiopharmaceutical or a radiopharmaceutical
3 analog,
4 determining the patient's mass and maximum effective mass,
5 selecting the lower of the patient's mass and maximum effective mass,
6 determining the activity hours for the radiopharmaceutical or the radiopharmaceutical
7 analog based on the lower of the patient's mass or maximum effective mass and the desired total
8 body dose,
9 administering a tracer dose of the radiopharmaceutical or a radiopharmaceutical analog
10 to the patient,
11 determining the residence time for the radiopharmaceutical or the radiopharmaceutical
12 analog, and
13 establishing the optimal effective activity amount, usually in mCi units, of the
14 radiopharmaceutical for the patient by calculating the therapeutic dose based on the following
15 equation:

$$\text{therapeutic dose} = \frac{\text{Activity Hours}}{\text{Residence time}} \times \frac{\text{desired total body dose}}{\text{maximum tolerated dose}}$$

(Equation VII).

16
17
18
19
20
21 The patient-specific dosimetry taught herein is a simplified method for determining the
22 therapeutic dose of a radiopharmaceutical to be administered to an individual patient and
23 involves the following two steps: (a) administration of a tracer or dosimetric dose of the
24 radiopharmaceutical or its analog followed by sequential measurement of the elimination
25 kinetics of the tracer or dosimetric dose from the whole body, and (b) calculation of the
26 therapeutic dose to be administered to the individual patient. The calculation may be done by a
27 human or computer-assisted, as discussed above. Further, it may be advantageous to generate a
28 dosimetry nomogram that takes into account the M or MEM and the residence time, and
29 indicates the mCi amount necessary to deliver the desired TBD. The nomogram may be set up in
30 a paper or slide rule format. The therapeutic dose can then be administered according to any

1 appropriate protocol, e.g. immediately preceded by predosing with a non-radiolabeled form of
2 the radiopharmaceutical or according to a prescribed schedule.

3 The simplified patient-specific dosimetry method is based in part on the following
4 observations: (a) knowledge of the pattern of radioactivity clearance from the whole body for a
5 particular radiopharmaceutical, e.g. one that takes the form of a monoexponential function
6 allows the residence time to be graphically estimated with fewer observations, (b) the activity
7 hours necessary to deliver a specific total body dose may be determined for a variety of body
8 masses, (c) radiopharmaceuticals generally do not accumulate in fat tissue, (d) dose should be
9 attenuated for reduced platelet counts or other physiological factors within the judgment of the
10 physician, and (e) most importantly, the tracer doses predict the behavior of subsequent therapy
11 doses.

12 Although subsequent treatment of the patient with the radiopharmaceutical after
13 performance of the methods of the invention is specifically contemplated, the methods taught
14 herein may be utilized for other purposes.

15 Depending on the radiopharmaceutical used, there may be little patient-to-patient
16 variability or such variability may be safely within the acceptable range for a given treatment
17 protocol. For this situation, it is possible to use the claimed methods on one or a few patients to
18 establish an optimal treatment dose or dose range of the radiopharmaceutical (perhaps obtained
19 in a mCi/kg or mCi/m² form) and thereafter to treat all patients with the dose or within the dose
20 range elucidated through use of the methods of the invention, perhaps with slight variations due
21 to the individual patient's characteristics such as tumor burden, body size, or blood counts.

22 Although treatment and pre-treatment dosimetric evaluation of humans is specifically
23 contemplated, the methods may also find veterinary usage. Additionally, the use of an animal
24 model may be useful to obtain information on the radiopharmaceutical and may be used in
25 specific steps of the method, such as establishing a clearance profile or predicting a maximum
26 tolerated dose in humans.

28 **Computer implementation**

29 The invention may also be implemented in a computer system or in software. In such a
30 case, the invention may be embodied in a computer system that is programmed or configured to
31 execute the required methods for determining the dose of the radiopharmaceutical. Further, the

1 invention may be embodied in a data storage device that is readable by a machine, embodying a
2 set of instructions executable by the machine to perform the required methods of determining the
3 dose of the radiopharmaceutical. Still further, the invention may be embodied in a computer
4 program product comprising a computer usable medium having computer readable program code
5 embodied therein for determining the dose of the radiopharmaceutical.

6 In the preferred embodiment, as shown schematically in **Figure 6**, the computer system
7 of the invention is a conventional personal computer 20 that includes, amongst other things, a
8 keyboard 22, display 24, cursor pointing device/mouse 26, hard drive 28, RAM 30, central
9 processing unit 32, modem or network card 34 and printer 36. The personal computer may run
10 any one of a number of operating systems, such as Windows, Mac-OS, Linux, or Unix. The
11 computer is programmed to execute the methods of the invention using a program written in any
12 suitable programming language, compiled into object code if required. In the preferred
13 embodiment, the programming is accomplished using a platform-independent programming
14 language such as Java, running within an Internet browser environment such as Netscape
15 Navigator or Windows Internet Explorer. Use of the Java language provides ease of distribution
16 and updating of the program because of the platform independent nature thereof. Also, if the
17 personal computer is connected to the Internet, the method can be run as an "applet" of program
18 instructions that is downloaded as required from a host computer 38 via the Internet or other
19 network 40 into the computer data storage device (RAM 30 or hard drive 28). The "applet" (or
20 other software) is transmitted from the host computer embodied in an analog and/or digital
21 carrier wave that is read by the computer to extract the "applet" from the carrier wave.

22 It will of course be appreciated that any suitable general purpose or dedicated computing
23 device running appropriate software or firmware may be used.

24 The computer 20 receives instructions for implementing the method of the invention from
25 the data storage device (for example the hard drive 28 or other magnetic storage medium, CD-
26 ROM or other optical storage medium, ROM, RAM 30 or other electronic storage medium, or
27 any other data storage device) that is readable by the computer 20. The data storage device
28 embodies a set of instructions executable by the computer to perform the methods of determining
29 the dose of the radiopharmaceutical as described below. Still further, the invention may be
30 embodied in a computer usable medium (for example a data storage device, an analog or digital

1 carrier wave or a printed medium) having computer readable program code embodied therein for
2 determining the dose of the radiopharmaceutical according to the method described below.

3 The preferred method of determining the dose of the radiopharmaceutical is shown in
4 flowchart form in **Figures 2-5**. The flowchart is applicable to the computer system of the
5 invention, the data storage device of the invention, and the computer usable medium of the
6 invention.

7 At the commencement of the computer-implemented method, the user selects which
8 radiopharmaceutical treatment is to be administered to the patient, step 110.

9 Then, patient-specific data is entered by the user, step 120. As illustrated, this includes
10 patient mass, height and gender, but further details such as patient name, age and health
11 insurance details are typically also entered. The data are typically gathered over a number of
12 days. Accordingly, in the preferred implementation of the method, a record is created for each
13 patient, which can then be updated as new data is gathered, until the method is complete.

14 After the patient-specific data is gathered, the patient's MEM is determined from the
15 patient's height and gender, step 130. This may be done from separate databases or tables of
16 MEM vs. patient height for men and women (see **Table 1**, e.g.) or alternatively a formula may be
17 used.

18 Then it is determined whether the patient mass is greater than the MEM, step 140. If so,
19 the mass (M) to be used in the method is set equal to the maximum effective mass, step 150. If
20 not, the mass M is set equal to the patient mass, step 160.

21 At step 170, the required activity hours to deliver a Maximum Tolerated Dose for the
22 procedure is determined from the mass M. This is again typically done using a table or database
23 (see **Table 2**, e.g.), or a formula, or a combination.

24 Turning now to **Figure 3**, the Maximum Tolerated Dose for the procedure is displayed,
25 step 180, and classes of patients who have a lower tolerance to the treatment are displayed, step
26 190. The user then selects whether or not the patient is in a lower tolerance class, step 200.

27 If the patient is in a lower tolerance class, the user selects the lower tolerance class to
28 which the patient belongs, step 210, and the desired Total Body Dose is set for the patient from a
29 table of lower tolerance classes vs. Total Body Doses, step 220.

30 If the patient is not in a defined lower tolerance class, the desired Total Body Dose is set
31 equal to the Maximum Tolerated Dose, step 230.

1 The desired Total Body Dose is then displayed to the user, step 240, and confirmation is
2 requested from the user as to whether or not this desired Total Body Dose is to be used, step 250.
3 If, in the discretion of the user (typically a physician), the displayed Total Body Dose is not to be
4 used, the desired Total Body Dose is input by the user, step 260.

5 Turning now to **Figure 4**, the initial radiotracer activity count and the date and time of
6 day are entered, step 270. This entry may be a single activity count, or it may take the form of a
7 number of readings (e.g. anterior scan reading, posterior scan reading, anterior background
8 reading, posterior background reading,) which are then subtracted and meaned as described
9 above (by the computer system) to provide a background corrected activity count reading, step
10 280. The entry of date and time is also optional, but is strongly preferred for record keeping and
11 also to allow the computer itself to calculate the elapsed times between subsequent readings. If
12 the initial date and time are not entered, the initial activity counts are considered to have been
13 taken at zero elapsed time.

14 Then the subsequent activity counts and dates and times are entered, step 290. As for the
15 initial activity counts, these entries may be single activity counts, or they may take the form of a
16 number of readings (e.g. anterior scan reading, posterior scan reading, anterior background
17 reading, posterior background reading,) which are then subtracted and meaned as described
18 above (by the computer system) to provide a background corrected activity counts. Also, as an
19 alternative to the entry of dates and times, subsequent readings may be based on entry of elapsed
20 time. Again, the preferred method is the entry of date and time, for record keeping and to reduce
21 errors in the calculation of elapsed times. If date and time entries are used, the computer
22 calculates the elapsed time for the subsequent activity counts. In the preferred embodiment, at
23 least two subsequent activity counts are conducted, and the residence time is calculated.

24 The residence time is then calculated from the formula for residence time set out above,
25 or by using a curve fit to the data, also as set out above, step 300. In the preferred embodiment,
26 the residence time is based on the initial activity count (100% activity), two subsequent activity
27 counts, and a 37% injected activity level, which is equal to the residence time, but this can be
28 varied according to the particular treatment.

29 Turning now to **Figure 5**, the therapeutic dose is calculated from the calculated activity
30 hours, the residence time, the desired Total Body Dose and Maximum Tolerated Dose, step 310.

1 The therapeutic dose is then provided to the user as an output, step 320. This can be done
2 by means of the display 24, the printer 36, or another output device. Alternatively, the output and
3 other data may be transmitted over the network or Internet 40 for use at the host 38 or at another
4 location.

5 While the computer and software implemented method has been described in the
6 flowchart in a linear manner in a particular order, it will be appreciated that the order of the steps
7 in the flowchart can be varied, and the user of the system may be permitted to jump between
8 various steps to permit the entry and amendment of data as necessary. In particular, the user may
9 be presented with a display in the form of a table or spreadsheet into which the data are entered.
10 Also, while the data are entered manually in the described embodiment, in an alternative
11 embodiment the data are captured directly from the gamma camera or other imaging device, so
12 that the software operates on a signal that is directly related to the physical parameter of the
13 activity of the radiotracer in the patient.

14 Also, the data captured may be more extensive than described above. For example, the
15 particular details of the gamma camera (name, collimator, camera height from table, body scan
16 field of view, body scan speed, calibration details) or other details of the procedure may be
17 captured to permit further analysis.

18 Further, a graph of the percentage activity vs. the time from the initial dose may be
19 displayed to the user, with the data points shown together with or without a fitted curve. The user
20 can then use their judgement or estimation to verify or select the residence time.

21 Still further, the software may provide a preliminary estimate of the residence time after
22 only the first subsequent activity count has been taken. This preliminary estimate of the
23 residence time can then be used to provide a preliminary estimate of the required dose. If this
24 preliminary estimate of the required dose exceeds the volume of the supplied vial of the
25 therapeutic radiopharmaceutical, the software provides a warning to the user that another vial of
26 the radiopharmaceutical may be required in the therapeutic procedure.

27 Finally, the software will include typical range constraint checking for the entered data.
28 For example, if the patient's weight is below 75 lb. or above 300 lb., a confirmation is required.
29 Similarly, the user will be notified if the time lapse between initial and subsequent counts is
30 outside expected ranges, or the activity counts show an increase with passing time, or the
31 day/date entries are not in the required format.

1
2
3 The invention now being generally described, the same will be better understood by
4 reference to the following detailed example, which is offered for illustration only and is not to be
5 considered limiting of the invention unless otherwise specified.
6

7 EXAMPLE

8 A radioimmunotherapy method utilizing ¹³¹I-labeled Anti-B1 (murine anti-CD20)
9 monoclonal antibody as the radiopharmaceutical is useful for treatment of non-Hodgkin's
10 lymphoma. A fundamental consideration with the anti-CD20 monoclonal antibody is that the
11 antibody while binding with high affinity to malignant cells of non-Hodgkin's lymphoma, also
12 cross-reacts with normal circulating B cells in the blood and with normal splenic B cells. Due to
13 this cross-reactivity, the variable B-cell population, and the preferred radioimmunotherapy
14 protocol with a dose ranging design in which patients receive varying amounts of unlabeled
15 antibody prior to the administration of the radiolabeled antibody, it was expected (and
16 subsequently observed) that there would be substantial patient-to-patient variability in the rate of
17 clearance of the radiopharmaceutical from the body. Thus, with varying clearance rates of the
18 ¹³¹I-labeled Anti-B1 antibody radiopharmaceutical, differing radiation doses would be delivered
19 per millicurie administered, even if patients had identical masses or body surface areas.
20 Therefore, optimization of the treatment dose on a patient-specific basis through the methods of
21 the present invention provides significant advantages.

22 A dose escalation study was performed previously in a range of 25cGy up to 85cGy (as
23 described in Kaminski, M.S. et al., "Iodine-131-Anti-B1 Radioimmunotherapy for B-cell
24 Lymphoma," J. Clin. Oncol., 14:1974-1981 (1996)). From this study, it was determined that in
25 patients who had not previously received a bone marrow transplant, the MTD was 75 cGy. The
26 desired TBD was therefore set at 75 cGy for the majority of patients (having a baseline platelet
27 count of $\geq 150,000$ cells/mm³) and set at 65 cGy for patients with a baseline platelet count greater
28 than 100,000 and less than 150,000 cells/mm³. The lower desired TBD for the subgroup was set
29 after a higher frequency of hematologic toxicity was noted in patients with reduced platelet
30 count.

Gamma cameras had either a single-head or dual-head configuration with a large or an extra large field of view and were equipped with a medium- or high-energy parallel hole collimator suitable for performing whole body scans and whole body counts with ^{131}I . A 5×10^6 count $^{99\text{m}}\text{Tc}$ extrinsic flood image using the ^{131}I collimator(s) was obtained at some point before using gamma camera images for dose calculations. Camera extrinsic uniformity with the ^{131}I collimator was assessed periodically using $^{99\text{m}}\text{Tc}$ or ^{57}Co as a source with imaging at the appropriate window. Inspection for collimator defects was visual. An intrinsic ^{131}I flood image of 5×10^6 counts was also performed. The dose calibrator used for dispensing patient doses was calibrated (checked for constancy) each day that it was used to quantitate radioactivity. Calibration with a National Institute of Standards and Technology (NIST)-traceable ^{131}I source was performed on a daily basis in addition to routine quality control of accuracy and linearity.

Camera sensitivity was performed each day prior to obtaining the patient whole body counts. A liquid source of a calibrated amount of ^{131}I (typically 200-250 μCi initial activity) was scanned to determine the counting efficiency (background corrected CPM/ μCi). This was performed to assure that the same collimator, scanning speed, window setting, and geometry was maintained at each imaging time point.

Anterior and posterior NaI probe counts (collimated thyroid uptake probe) at 2.5 meters from the patient were acquired for 1 minute per view with the patient seated on a stool. One minute background counts were also taken at each measurement time. The photopeak was centered at 364 keV with a symmetric window of 314 to 414 keV. The probe was pointed midway between the patient's umbilicus and xyphoid. Patient counts were acquired immediately post infusion (within 1 hr) of the radiopharmaceutical (in a 5 mCi amount for dosimetry) before voiding (to determine 100% infused activity), then daily for 5 to 8 days (these latter counts were acquired after voiding). Probe response as a function of various positions of a point source of ^{131}I was measured at 2.5 meters from the probe. Results show that the probe used in this study had a response of $\pm 10\%$ over a circular diameter of 25 inches with the source centered in the probe field-of-view at 2.5 meters. Routine clinical quality control procedures for the probe involved daily counts from a Ba-133 source of known activity. Ba-133 quality control data showed counts generally were within $\pm 2\%$ of the expected counts.

Whole body imaging was performed immediately after room background determination. The prepared tracer activity was measured in a dose calibrator and recorded. The diagnostic

1 scans were obtained at three time points (Day 0; Day 2, 3, or 4; and Day 6 or 7 post-infusion).

2 The computer and gamma camera for whole body scans and background were as follows:

- 3 • Medium- or high. energy parallel hole collimator
- 4 • Symmetric window centered on the 364 keV photopeak of ^{131}I (314–414 keV)
- 5 • Matrix: minimum 128 x 128
- 6 • Scan speed: 30 cm/min.

7 Background counts were taken immediately after the quality control procedure and before the
8 patient entered the room (while the patient was a considerable distance from the room). The
9 average background rate for a particular gamma camera and collimator were established. If
10 abnormal high or low background counts were measured, reasons for variation (appropriate set-
11 up or identification of other radioactive sources) were assessed and corrective actions were
12 performed. The same region of interest used for patient counts was used for the background
13 counts.

14 Anterior and posterior whole body images were obtained. For any particular patient, the
15 same gamma camera, collimator, and scanning speed were used for all scans. Extremities were
16 included in the images and the arms were not allowed to cross over the body. The camera head(s)
17 were brought as close to the patient as possible; the posterior view was obtained with the camera
18 head directly below the imaging table. The scans were centered on the midline of the patient. A
19 rectangular ROI was drawn around the entire field of view to obtain separate anterior (C_a) and
20 posterior (C_p) counts. The time of the images and the total body counts were recorded.

21 The patient is a 63-year-old, 5' 6" man weighing 90 kg. His baseline platelet count is
22 121,000 cells/mm³ and his % injected activities from 1, 72, and 164 hr were 100%, 50%, and
23 20%, respectively. From **Table 1**, his maximum effective mass is determined to be 88.5 kg.
24 Because his maximum effective mass is less than his actual mass, the maximum effective mass is
25 used to look up the value for activity hours from **Table 2**. The activity hours are 9490 mCi•hr.
26 By plotting the % injected activity values on **Figure 7**, the residence time is determined to be
27 103 hours. As the patient's platelet count is greater than 100,000 and less than 150,000
28 cells/mm³, the desired TBD is 65 cGy. The equation for the therapeutic dose (mCi) is then
29 solved as follows:

1
$$\text{Therapeutic Dose (mCi)} = \frac{9490 \text{ mCi h}}{103 \text{ h}} \times \frac{65 \text{ (cGy)}}{75 \text{ cGy}} = 80 \text{ mCi } ^{131}\text{I} - \text{Labeled Radiopharmaceutical}$$

2
3 The patient is therefore given 80 mCi of the radiopharmaceutical at the treatment stage.

4 Notably, a 75 cGy dose target of this radiopharmaceutical often resulted in therapeutic
5 doses ranging from 58 to 149 mCi for a group of patients treated, thereby demonstrating the need
6 for the patient-specific dosimetry method of the present invention.

7
8
9 In summary, the patient-specific whole body dosimetric approach assumes uniform
10 deposition of activity in an ellipsoid to approximate the patient's biodistribution. While not fully
11 capable of dealing with heterogeneous distribution of tracer activity, the simplicity of the
12 approach, coupled with its ease of use make it attractive as a clinically realistic method for
13 prospectively determining the millicurie dose for treatment of a given patient with a
14 radiopharmaceutical.

15 All publications and patent applications mentioned in this specification are herein
16 incorporated by reference to the same extent as if each individual publication or patent
17 application was specifically and individually indicated to be incorporated by reference.

18 The invention now being fully described, it will be apparent to one of ordinary skill in the
19 art that many changes and modifications can be made thereto without departing from the spirit or
20 scope of the appended claims.